870640-62-3

Basic information

• Product Name: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol
• Synonyms: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol
• CAS NO: 870640-62-3
• Molecular Weight: 221.343
• Mol File: 870640-62-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol(870640-62-3)
• EPA Substance Registry System: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol(870640-62-3)

Safety Data

• Hazardous Substances Data: 870640-62-3(Hazardous Substances Data)

Usage

General Description

"(2S,3S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol" is a chemical compound with the molecular formula C14H23NO. It is a chiral compound, meaning it has a non-superimposable mirror image, and is commonly used in pharmaceutical research and drug synthesis. The compound contains a benzyl group, a methyl group, and an amino group, as well as a hydroxyl group, making it a versatile building block for various organic reactions and syntheses. It is important to note that this compound has stereochemistry, which can impact its biological activity and pharmacological properties. Overall, "(2S,3S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol" is a valuable and versatile chemical compound with several potential applications in the field of chemistry and medicine.

Upstream product

• 1859-49-0 (2S,3S)-2-(benzylamino)-3-methylpentanoic acid 
• 100-52-7 benzaldehyde 
• 73-32-5 L-isoleucine 
• 658691-27-1 C₁₃H₁₇NO₂ 
• 4125-97-7 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanoic acid 

Downstream Products

• 870640-63-4 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanal 
• 870640-61-2 (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine 
• 870640-64-5 tert-butyl (3R,4S,5S)-4-[benzyl(methyl)amino]-3-methoxy-5-methyl heptanoate 
• 1438852-21-1 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 669074-47-9 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-amino-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 120205-48-3 tert-Butyl (3R,4S,5S)-3-methoxy-4-(N-methylamino)-5-methylheptanoate hydrochloride 
• 120205-52-9 tert-butyl (3R,4S,5S)-4-[(2S)-2-[[(benzyloxy)carbonyl]amino]-N,3-dimethylbutanamido]-3-methoxy-5-methylheptanoate 

Relevant articles and documents

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I): where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: ■ a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ■ -(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ■ an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ■ a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.